Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2007; 7(5):332-334
Effectiveness and pharmacoeconomic evaluation of rituximab for treatment of non-Hodgkin's lymphoma
1. SHI Hao-qiang1(1.Department of Pharmacy, Ruijin Hospital, Medical College of Shanghai Jiaotong University, Shanghai 200025,China shihaoqiang@126.com)
2. SHEN Yang2( 2.Department of Hematology, Ruijin Hospital, Medical College of Shanghai Jiaotong University, Shanghai 200025,China )
3. YE Ying-qiong1(1.Department of Pharmacy, Ruijin Hospital, Medical College of Shanghai Jiaotong University, Shanghai 200025,China )
4. ZHANG Fen-qin2( 2.Department of Hematology, Ruijin Hospital, Medical College of Shanghai Jiaotong University, Shanghai 200025,China )
5. TAO Jing1(1.Department of Pharmacy, Ruijin Hospital, Medical College of Shanghai Jiaotong University, Shanghai 200025,China )
6. CAI Wei-min1(1.Department of Pharmacy, Ruijin Hospital, Medical College of Shanghai Jiaotong University, Shanghai 200025,China )
ABSTRACT  Objective:To elucidate the efficacy and adverse drug reaction of rituximab in treatment of non-Hodgkin's lymphoma. Methods: According to the oversea investigation and research carried out in the department of hematology in Ruijin Hospital, untraditional pharmacoeconomic method was used to evaluate the therapeutic protocol of rituximab. Results: Rituximab plus CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) had better therapeutic results in the treatment of non-Hodgkin's lymphoma than traditional CHOP chemotherapy alone in the aspect of pharmacoeconomics.Conclusion: Rituximab is a fine and phamacoeconomic choice for non-Hodgkin's lymphoma with satisfactory efficacy and safety.
Welcome to PCAR! You are the number 1599 reader of this article!
Please cite this article as:
SHI Hao-qiang1,SHEN Yang2,YE Ying-qiong1,ZHANG Fen-qin2,TAO Jing1,CAI Wei-min1,. Effectiveness and pharmacoeconomic evaluation of rituximab for treatment of non-Hodgkin's lymphoma[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2007; 7(5): 332-334.
References:
1. WANG Yu-Luan, MI Zhen-Guo. Modern non-Hodgkin's lymphoma[M]. People's Military Medical Press, 2003,():9-15
2. Reff M E, Carner K, Chambers K S, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20[J]. Blood, 1994,83(2):435-445
3. Akhtar S, Maghfoor I. Rituximab plus CHOP for diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002,346(23):1830-1831
4. Cheson B D. CHOP plus rituximab-balancing facts and opinion[J]. N Engl J Med, 2002,346(4):280-282
5. McLaughlin P, Grillo-Lopez A J, Link B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program[J]. J Clin Oncol, 1998,16(8):2825-2833
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002,346(4):235-242
7. Knight C, Hind D, Brewer N,et al. Rituximab(Mab Thera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation[J]. Health Technol Assess, 2004,8(37):iii, ix-xi, 1-82
8. Mounier N, Gisselbrecht C, Briere J, et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte[J]. J Clin Oncol, 2004,22(14):2826-2834
9. Groot M T, Lugtenburg P J, Hornberger J, et al. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands[J]. Eur J Haematol, 2005,74(3):194-202
10. LIN Tong-Yu, ZHANG Hong-Yu, HUANG Yan, et al. Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail[J]. Chinese Journal of Cancer, 2005,24(12):1421-1426
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口